BioCentury
ARTICLE | Clinical News

LiRIS: Phase II started

April 8, 2013 7:00 AM UTC

Taris began a double-blind, placebo-controlled, U.S. and Canadian Phase II trial to evaluate a single dose of 400 mg LiRIS in up to 124 patients. The trial includes an open-label extension study. ...